| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SHISA4 |
| Uniprot No | Q96DD7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-197aa |
| 氨基酸序列 | MPPAGLRRAAPLTAIALLVLGAPLVLAGEDCLWYLDRNGSWHPGFNCEFFTFCCGTCYHRYCCRDLTLLITERQQKHCLAFSPKTIAGIASAVILFVAVVATTICCFLCSCCYLYRRRQQLQSPFEGQEIPMTGIPVQPVYPYPQDPKAGPAPPQPGFIYPPSGPAPQYPLYPAGPPVYNPAAPPPYMPPQPSYPGA |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SHISA4重组蛋白的3篇虚构参考文献示例，供参考：
1. **文献名称**：*SHISA4 Recombinant Protein Suppresses Wnt/β-Catenin Signaling in Colorectal Cancer Cells*
**作者**：Li, X., et al.
**摘要**：本研究通过表达纯化SHISA4重组蛋白，发现其能竞争性结合Wnt受体LRP6.抑制β-catenin核转位，从而抑制结直肠癌细胞增殖和迁移，为靶向治疗提供新思路。
2. **文献名称**：*Structural and Functional Analysis of SHISA4 in Gastric Cancer Metastasis*
**作者**：Wang, Y., & Zhang, H.
**摘要**：文章解析了SHISA4重组蛋白的晶体结构，并通过体外实验证明其通过阻断FGF信号通路抑制胃癌细胞侵袭，揭示其作为转移抑制因子的分子机制。
3. **文献名称**：*High-Yield Production of SHISA4 Recombinant Protein in E. coli and Its Anti-Tumor Activity*
**作者**：Kim, S., et al.
**摘要**：报道了一种利用大肠杆菌高效表达SHISA4重组蛋白的工艺，验证了纯化蛋白在体外可诱导卵巢癌细胞凋亡，且无明显细胞毒性，具备药物开发潜力。
---
注：以上内容为模拟示例，实际文献需通过PubMed、Web of Science等数据库检索。如需真实文献支持，请提供更多上下文或具体研究背景。
**Background of SHISA4 Recombinant Protein**
SHISA4. a member of the SHISA family of single-pass transmembrane proteins, plays a critical role in regulating cellular signaling pathways, particularly the Wnt/β-catenin pathway. Initially identified in developmental studies, SHISA proteins are evolutionarily conserved and function as adaptors or antagonists to modulate receptor trafficking, stability, or ligand-receptor interactions. SHISA4 is characterized by an N-terminal cysteine-rich domain (CRD) essential for ligand binding and a C-terminal transmembrane domain anchoring it to the endoplasmic reticulum (ER) or plasma membrane.
The recombinant SHISA4 protein is engineered to study its molecular interactions and therapeutic potential. It is typically produced using expression systems like *E. coli* or mammalian cells, followed by purification via affinity tags (e.g., His-tag). Recombinant SHISA4 retains functional domains, enabling researchers to explore its role in inhibiting Wnt signaling by promoting the degradation of Frizzled receptors or disrupting ligand-receptor complexes. Dysregulation of SHISA4 has been linked to diseases such as cancer, where aberrant Wnt signaling drives tumor progression, and neurodegenerative disorders.
Studies highlight SHISA4's dual context-dependent roles: it suppresses tumor growth in certain cancers but may promote metastasis in others. Additionally, it influences neuronal differentiation and tissue patterning during embryogenesis. Recombinant SHISA4 serves as a tool for *in vitro* assays, animal models, and drug screening, offering insights into its mechanism and potential as a therapeutic target. Its development underscores the growing interest in targeting regulatory proteins to restore signaling homeostasis in disease.
×
